第一条 为进一步建立健全宁夏中科生物科技股份有限公司（以下简称"公 司"）董事及高级管理人员的考核和薪酬管理制度，完善公司治理结构，根据《中 华人民共和国公司法》《上市公司治理准则》《上市公司独立董事管理办法》《公 司章程》及其他有关规定，公司特设立董事会薪酬与考核委员会，并制定本实施 细则。 第二条 公司董事会下设薪酬与考核委员会，主要负责制定董事、高级管理 人员的考核标准并进行考核，制定、审查董事、高级管理人员的薪酬政策与方案， 并向董事会提出建议。 宁夏中科生物科技股份有限公司 董事会薪酬与考核委员会实施细则 二О二五年四月二十六日 1 第一章 总 则 第三条 本实施细则所称董事是指在公司支取薪酬的董事长、董事；高级管 理人员是指董事会聘任的总经理、副总经理、董事会秘书、财务总监及其他高级 管理人员。 第二章 人员组成 第四条 薪酬与考核委员会成员由三名董事组成，独立董事占多数。 第五条 薪酬与考核委员会委员由董事长、二分之一以上独立董事或全体董 事的三分之一提名，并由董事会选举产生。 第六条 薪酬与考核委员会设召集人一名，由独立董事委员担任，负责主持 委员会工作；召集人在委员内选举，并报请董事会批准产 ...

宁夏中科生物科技股份有限公司 第四条 股东会应当在《公司法》和公司章程规定的范围内行使职权。 第五条 股东会分为年度股东会和临时股东会。年度股东会每年召开一次， 应当于上一会计年度结束后的 6 个月内举行。临时股东会不定期召开，出现《公 司法》第一百一十三条规定的应当召开临时股东会的情形时，临时股东会应当在 2 个月内召开。 股东会议事规则 二 O 二五年四月二十六日 1 第一章 总 则 第一条 为规范宁夏中科生物科技股份有限公司（以下简称："公司"）行为， 保证股东会依法行使职权，根据《中华人民共和国公司法》（以下简称《公司法》）、 《中华人民共和国证券法》（以下简称《证券法》）、《上市公司股东会规则》的规 定，修订本规则。 第二条 公司股东会的召集、提案、通知、召开等事项适用本规则。 第三条 公司应当严格按照法律、行政法规、公司章程及本规则的相关规定 召开股东会，保证股东能够依法行使权利。 公司董事会应切实履行职责，认真、按时组织股东会。公司全体董事应当勤 勉尽责，确保股东会正常召开和依法行使职权。 公司在上述期限内不能召开股东会的，应当报告公司所在地中国证券监督管 理委员会（以下简称：中国证监会）宁夏证 ...

证券代码：600165 股票简称：*ST 宁科 公告编号：临 2025-054 宁夏中科生物科技股份有限公司 关于再次延期回复上海证券交易所对公司 2024 年 年度报告的信息披露监管问询函的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁夏中科生物科技股份有限公司（以下简称：公司）于 2025 年 3 月 31 日收 到上海证券交易所（以下简称：上交所）下发的《关于宁夏中科生物科技股份有 限公司 2024 年年度报告的信息披露监管问询函》（上证公函【2025】0318 号） （以下简称：《年报问询函》），并要求公司在 10 个交易日内进行书面回复并履行 信息披露义务。具体内容详见公司于 2025 年 4 月 1 日披露的《收到<关于宁夏中 科生物科技股份有限公司 2024 年年度报告的信息披露监管问询函>的公告》（公 告编号：临 2025-047）。 公司收到《年报问询函》后高度重视，积极组织各方对所涉及的相关问题进 行逐项回复。鉴于《年报问询函》需回复的部分问题涉及的数据量较大，部分内 容需要进一步补充和完善，因此 ...

Core Viewpoint - The new delisting regulations in A-shares are intensifying, leading to an accelerated "survival of the fittest" process in the market, with a recent surge in delisting risk warnings from multiple companies [1] Group 1: Companies at Risk - ST Xintong is facing delisting risk due to 368 million yuan in non-operating fund occupation, with a two-month deadline for rectification [2] - ST Ningke is projected to incur a loss of 580 to 650 million yuan in 2024, with non-deductible revenue below 300 million yuan, risking delisting if the annual report receives an "unable to express opinion" audit [5][6] - ST Dayao has seen its market value drop below 500 million yuan, making it the first trading delisting stock of 2025, with a stock price plummeting to 1.18 yuan [7][8] - ST Modern has not completed regulatory rectification on time and risks delisting if it fails to submit an audit proof within two months [9][10] Group 2: Regulatory Background - The 2025 delisting regulations have tightened financial indicators, including continuous losses, revenue below 300 million yuan with negative net assets, and excessively low market value [11] - Regulatory scrutiny on information disclosure violations and financial fraud has intensified, exemplified by the case of Dongfang Group, which inflated revenue by 16.1 billion yuan over four years [11] Group 3: Investor Guidance - Investors are advised to avoid high-risk stocks, particularly ST and *ST stocks, companies with continuous losses, and those with abnormal stock price fluctuations [12] - Caution is advised against "doomsday speculation," as some ST stocks may experience short-term surges followed by sharp declines due to major shareholders offloading [13] - Investors should focus on the quality of financial reports, particularly looking for non-standard audit opinions and issues related to major shareholder fund occupation [14] - A rational perspective on "shell protection" expectations is necessary, as the accelerated delisting process under new regulations poses high risks for speculative bottom-fishing [15]

Investment Rating - The report does not explicitly state an investment rating for the synthetic biology industry Core Insights - The synthetic biology sector is experiencing a global technological revolution, providing innovative solutions to major challenges such as health, climate change, and food security, as highlighted by the National Development and Reform Commission's "14th Five-Year Plan for Bioeconomic Development" [4] - The Huazhong Securities synthetic biology index, which includes 58 companies across various sectors, has seen a decline of 9.66% recently, underperforming compared to the Shanghai Composite Index [5][17] Industry Market Dynamics - The synthetic biology sector's stocks have performed poorly recently, with a 9.66% drop, ranking 32nd among sectors [17] - The top five gainers in the synthetic biology sector include: - Novozymes (+27%) - Shandong Heda (+10%) - Yaxiang Co. (+10%) - Pro Pharma (+3%) - Huafeng Chemical (+2%) [18] - The top five losers include: - Xinri Hengli (-18%) - Kasei Biotech (-12%) - Yabao Chemical (-9%) - Berry Genomics (-7%) - Weilan Bio (-6%) [22] Company Business Developments - Anhui Pucan has launched the world's largest CO₂-based polycarbonate production facility, with an annual capacity of 50,000 tons, expected to generate sales of 1.5 billion yuan [23] - Huafeng Chemical plans to acquire two subsidiaries to integrate its polyurethane supply chain, with projected revenues exceeding 6.4 billion yuan in 2024 [23] - Tianchen Company signed a contract for a 100,000 tons/year bioethanol project in Egypt, marking its first venture into the North African market [24] - Kosemet announced a partnership with Shanghai Xinhai Biotechnology to develop bio-synthesized retinol for skincare products [25] Industry Financing Tracking - The synthetic biology sector has seen accelerated financing, with nearly 100 companies completing new funding rounds since the beginning of 2025 [28] - Zhongsheng Suyuan Biotechnology completed a B round financing of 235 million yuan, focusing on iPSC-derived cell therapies [28] - Korean company INTAKE raised approximately 9.2 million USD in a C round financing to develop precision fermentation proteins [29] Company R&D Directions - Jinbo Biotech received approval for its recombinant type III human collagen injection product, marking a breakthrough in high-end medical aesthetics [31] - CellX's mushroom protein received FDA GRAS certification, allowing it to enter the U.S. market [31] - MycoTechnology's truffle sweet protein product received FEMA GRAS certification, showcasing advancements in natural flavoring solutions [32] - Nourish Ingredients and Cabio Biotech successfully commercialized a precision fermentation fat product, enhancing the flavor of plant-based products [34]

Investment Rating - The report does not explicitly state an investment rating for the synthetic biology industry Core Insights - The synthetic biology sector is experiencing a global revolution, integrating into economic and social development to address major challenges such as health, climate change, and food security. The National Development and Reform Commission has issued the "14th Five-Year Plan for Bioeconomic Development," indicating a trillion-yuan market potential in the bioeconomy [4] Industry Market Dynamics - The synthetic biology index decreased by 9.66% to 1437.31 during the week of April 5-11, 2025, underperforming compared to the Shanghai Composite Index, which fell by 1.62%, and the ChiNext Index, which dropped by 4.21% [5][17] - The top five performing companies in the synthetic biology sector during this period were: - Novozymes (+27%) - Shandong Heda (+10%) - Yaxing Co. (+10%) - Pro Pharma (+3%) - Huafeng Chemical (+2%) [18] - The bottom five performing companies were: - Xinri Hengli (-18%) - Kasei Biotech (-12%) - Yaborn Chemical (-9%) - Berry Genomics (-7%) - Blue Biological (-6%) [22] Company Business Developments - Anhui Pucan launched the world's largest CO₂-based polycarbonate production facility, with an annual capacity of 50,000 tons, expected to generate sales of 1.5 billion yuan [23] - Huafeng Chemical plans to acquire two subsidiaries to integrate the polyurethane supply chain, with projected combined revenue exceeding 6.4 billion yuan in 2024 [23] - Tianchen Company signed a contract for a 100,000 tons/year bioethanol project in Egypt, marking its first venture into the North African market [24] Industry Financing Tracking - Synthetic biology companies are accelerating financing, with nearly 100 firms completing new rounds of funding since the beginning of 2025. Zhongsheng Suyuan Biotechnology raised 235 million yuan in its B round, focusing on iPSC-derived cell therapies [28][29] Company R&D Directions - Jinbo Biotech received approval for its recombinant type III human collagen injection product, marking a breakthrough in high-end medical aesthetics [31] - CellX's mushroom mycelium protein received FDA GRAS certification, allowing entry into the U.S. market [31] - MycoTechnology's truffle sweet protein ClearHT received FEMA GRAS certification, showcasing advancements in natural flavoring and health foods [32]

证券代码：600165 股票简称：*ST 宁科 公告编号：临 2025-052 宁夏中科生物科技股份有限公司 关于召开 2024 年度网上业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 4 月 18 日（星期五）15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 报 中 国 证 券 网 路 演 中 心 （ 网 址 ： http://roadshow.cnstock.com/） 会议召开方式：网络互动 投资者可于 2025 年 4 月 14 日（星期一）17:00 前将相关问题通过电子邮 件的形式发送至宁夏中科生物科技股份有限公司（以下简称：公司）邮箱： official@ningkeshengwu.com。公司将在信息披露允许范围内，在 2024 年度网上 业绩说明会对投资者普遍关注的问题进行回答。 公司已于 2025 年 3 月 15 日发布公司 2024 年年度报告，为便于广大投资者 更全面深入地了解公司 2024 年度经营成果、财务状况，公司计 ...